|Bid||36.20 x 100|
|Ask||50.00 x 100|
|Day's Range||39.25 - 40.60|
|52 Week Range||7.50 - 41.80|
|PE Ratio (TTM)||-11.63|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Zogenix, Inc. Here are 5 ETFs with the largest exposure to ZGNX-US. Comparing the performance and risk of Zogenix, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Zogenix, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 7.13 million, Net Earnings of USD -22.45 million. Gross margins narrowed from 1.29% to -15.68% compared to the same period last year, operating (EBITDA) margins now -299.17% from -812.26%. Change in operating cash ... Read more (Read more...)
Marijuana can reduce seizures in epilepsy patients, but Zogenix's ZX008 might control seizures even better.
Zogenix rocketed to its highest point in nearly seven years Monday after it announced a public offering of 4.3 million shares.
After reporting positive phase 3 results for its drug for Dravet syndrome last week, management announced a dilutive stock offering today to raise more capital.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Zogenix, Inc. a score of 16. Our analysis is based on comparing Zogenix, Inc. with the following peers – DURECT Corporation, Mallinckrodt Plc, Merck & Co., Inc., Antares Pharma, Inc., Nektar Therapeutics, Johnson & Johnson, Cardinal Health, Inc., Eli Lilly and Company, Alkermes Plc and Pfizer Inc. ... Read more (Read more...)
An experimental drug for a form of epilepsy saw strong early results, sending shares of an East Bay drug developer soaring Friday. Zogenix Inc. (ZGNX) said top-line results from a late-stage study of its drug, called ZX-008, showed that Dravet syndrome patients who were given the drug had fewer convulsive seizures than patients who received a placebo. A low dose of ZX-008, a liquid also known as fenfluramine hydrochloride, also showed improvements in the study's secondary targets, including an improvement in intervals between seizures.
Zogenix's low-dose fenfluramine may lower the rate of seizures in Dravet syndrome patients by more than GW Pharma's Epidiolex.
Zogenix rocketed Friday after reporting Phase 3 data of a seizure drug that widely topped earlier results from rival GW Pharma.
On Friday, shares of pharmaceutical company Zogenix Inc. (ZGNX) are skyrocketing after it announced positive results from its first Phase 3 study of ZX008, a drug used to treat the rare epilepsy form Dravet Syndrome.
Biotech news aplenty has breathed renewed life into the sector, driving those stocks and several ETFs to new highs.
Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals. In the trial, Zogenix's drug was superior to a placebo in reducing the number of seizures in children with Dravet syndrome, a genetic dysfunction in the brain.
The Emeryville, Calif.-based firm said its first Phase 3 study of ZX008 in Dravet syndrome achieved its primary endpoint. Dravet syndrome is a form of epilepsy.
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.
Shares of Zogenix zoom 150 percent after positive results from its experimental study for its treatment of a rare form of epilepsy.
Zogenix saw its shares more than double early on Friday after the company reported positive top-line results from its most recent late-stage trial in the treatment of Dravet syndrome.